Why Is Intra-Cellular (ITCI) Up 1.2% Since Last Earnings Report? [Yahoo! Finance]
Intra-Cellular Therapies Inc. (ITCI)
Last intra-cellular therapies inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intracellulartherapies.com/investor-relations
Company Research
Source: Yahoo! Finance
Will the recent positive trend continue leading up to its next earnings release, or is Intra-Cellular due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Intra-Cellular Q1 Loss Narrower Than Expected, Sales Beat Intra-Cellularreported first-quarter 2024 loss of 16 cents per share, narrower than the Zacks Consensus Estimate of a loss of 31 cents, primarily due to higher product sales. The company had incurred a loss of 46 cents per share in the year-ago quarter. Total revenues, comprising product sales and grant revenues, came in at $144.9 million compared with $95.3 million reported in the year-ago period. The top line beat the Zacks Consensus Estimate of $141.9 million. Quarter in Detail Caplyta, the only approved drug in Intra-Cellular's portfolio, was approved by the FDA in December 2019, for treating schizophrenia i
Show less
Read more
Impact Snapshot
Event Time:
ITCI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITCI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITCI alerts
High impacting Intra-Cellular Therapies Inc. news events
Weekly update
A roundup of the hottest topics
ITCI
News
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "neutral" rating re-affirmed by analysts at UBS Group AG. They now have a $83.00 price target on the stock, down previously from $85.00.MarketBeat
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $103.00 price target on the stock.MarketBeat
- Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe [Yahoo! Finance]Yahoo! Finance
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Mizuho from $96.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Canaccord Genuity Group Inc. from $107.00 to $113.00. They now have a "buy" rating on the stock.MarketBeat
ITCI
Earnings
- 5/7/24 - Beat
ITCI
Sec Filings
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- ITCI's page on the SEC website